Company Overview
Company Name
Mezzion Pharmaceuticals
Address
United States
Website
mezzion.comApprox. Annual Revenue
$7.2M
Employees
40
Established
2003
About Mezzion Pharmaceuticals
Mezzion is a United States-based company that is dedicated to discovering, developing, and delivering new hope for people living with Fontan circulation, a condition affecting single ventricle heart disease. The company is committed to shaping the future of the Fontan community through its scientific research, clinical trials, and support for those affected by the condition.
Business Profile
Read from the Mezzion Pharmaceuticals website on Oct 11, 2026. Hover an item to see the exact wording it came from.
About the website
- Website quality (AI-assessed)
- 7/10 · Clear navigation and content; Current copyright year; Professional design
- Footer copyright year
- 2025
- Website by
- Winn-Brown & Co
More Companies in California
Browse all companies in California →
Frequently Asked Questions about Mezzion Pharmaceuticals
Categories
Technologies Used
'%20fill='%23000000'%3e%3cg%20id='icons'%20transform='translate(56.000000,%20160.000000)'%3e%3cpath%20d='M102.8695,7446.25504%20C101.3625,7444.73916%2098.9185,7444.73916%2097.4115,7446.25504%20L91.2705,7452.43224%20C90.8935,7452.81045%2090.8935,7453.42505%2091.2705,7453.80428%20C91.6475,7454.1835%2092.2585,7454.1835%2092.6355,7453.80428%20L98.7755,7447.62809%20C99.5285,7446.86964%20100.7515,7446.86964%20101.5045,7447.62809%20C102.2585,7448.38552%20102.2585,7449.61473%20101.5045,7450.37317%20L95.4825,7456.43066%20C96.2355,7457.1881%2097.4575,7457.1881%2098.2115,7456.43066%20L102.8695,7451.74521%20C104.3765,7450.22933%20104.3765,7447.77092%20102.8695,7446.25504%20M100.8225,7448.31411%20C100.4455,7447.93488%2099.8345,7447.93488%2099.4575,7448.31411%20L93.3175,7454.49029%20C92.5635,7455.24874%2091.3415,7455.24874%2090.5885,7454.49029%20C90.2115,7454.11107%2089.6005,7454.11107%2089.2235,7454.49029%20C88.8465,7454.86952%2088.8465,7455.48412%2089.2235,7455.86233%20C90.7305,7457.37922%2093.1745,7457.37922%2094.6825,7455.86233%20L100.8225,7449.68615%20C101.1995,7449.30793%20101.1995,7448.69232%20100.8225,7448.31411%20M98.7755,7442.13691%20C97.2685,7440.62103%2094.8245,7440.62103%2093.3175,7442.13691%20L87.1765,7448.31411%20C86.8005,7448.69232%2086.8005,7449.30793%2087.1765,7449.68615%20C87.5535,7450.06537%2088.1645,7450.06537%2088.5415,7449.68615%20L94.6825,7443.50996%20C95.4355,7442.75151%2096.6575,7442.75151%2097.4105,7443.50996%20C97.7875,7443.88918%2098.3985,7443.88918%2098.7755,7443.50996%20C99.1525,7443.13073%2099.1525,7442.51613%2098.7755,7442.13691%20M96.7285,7444.19598%20C96.3515,7443.81675%2095.7405,7443.81675%2095.3645,7444.19598%20L89.2235,7450.37317%20C88.4695,7451.13061%2087.2485,7451.13061%2086.4945,7450.37317%20C85.7405,7449.61473%2085.7405,7448.38552%2086.4945,7447.62708%20L92.5175,7441.56959%20C91.7635,7440.81114%2090.5415,7440.81114%2089.7875,7441.56959%20L85.1295,7446.25504%20C83.6235,7447.77092%2083.6235,7450.22933%2085.1295,7451.74521%20C86.6375,7453.2621%2089.0805,7453.2621%2090.5885,7451.74521%20L96.7285,7445.56902%20C97.1055,7445.1898%2097.1055,7444.5752%2096.7285,7444.19598'%20id='squarespace-[%23132]'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
%20--%3e%3csvg%20version='1.1'%20id='st_x5F_cc_x5F_app_x5F_RGB.svg'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20viewBox='0%200%20240.0004%20234.0004'%20style='enable-background:new%200%200%20240.0004%20234.0004;'%20xml:space='preserve'%3e%3cstyle%20type='text/css'%3e%20.st0{fill:url(%23SVGID_1_);}%20.st1{fill:%23FFFFFF;}%20%3c/style%3e%3clinearGradient%20id='SVGID_1_'%20gradientUnits='userSpaceOnUse'%20x1='119.9997'%20y1='234.0002'%20x2='119.9997'%20y2='0.0002'%3e%3cstop%20offset='0'%20style='stop-color:%23201F21'/%3e%3cstop%20offset='1'%20style='stop-color:%23313131'/%3e%3c/linearGradient%3e%3crect%20x='-0.0003'%20y='0.0002'%20class='st0'%20width='240'%20height='234'/%3e%3cg%3e%3cpath%20class='st1'%20d='M132.24969,97.95853c-5.60328,18.77988-10.28088,36.91208-15.88416,54.63138%20c-3.18081,9.99579-6.66385,19.53729-11.05544,25.59485c-4.84678,6.81497-13.93402,13.32771-24.83743,13.32771%20c-7.72443,0-15.29683-3.63509-15.29683-11.66174c0-4.99789,5.14901-9.69264,9.23837-9.69264%20c2.42339,0,3.63508,1.36282,4.24046,2.42339c3.7862,6.81497,7.42128,10.75229,9.08724,10.75229s3.02878-2.27135,5.7544-12.1151%20l19.82331-73.26013H99.08337c-1.06058-3.18081,0.45427-7.11812,2.27135-7.87554h14.23625%20c2.72562-8.7841,5.92356-17.60862,10.46719-25.63529c6.81497-12.26713,17.7193-21.95976,32.71205-21.95976%20c11.3586,0,16.05333,5.45216,16.05333,12.41917c-0.15111,7.42036-6.66293,11.20656-9.69263,11.20656%20c-2.42247,0-3.63416-1.81709-4.39159-4.39159c-2.57451-9.69263-5.90643-12.57029-7.87555-12.57029%20c-1.9682,0-4.99789,3.63416-8.3289,11.20656c-4.3925,9.54151-7.28729,19.72977-10.01291,29.72464h17.26501%20c1.05966,2.12023,0.15112,6.66385-2.42339,7.87554H132.24969z'/%3e%3c/g%3e%3c/svg%3e)
Key Decision Makers
Kelly Williams Director Clinical Operations